Study affirms safety of adenosine test
Adenosine rest-stress perfusion may represent nearly half the imaging volume at some clinics, but due to safety questions some physicians are sticking with dobutamine for pharmacological stress testing.
Study affirms safety of adenosine test
By: James Brice
Adenosine rest-stress perfusion may represent nearly half the imaging volume at some clinics, but due to safety questions some physicians are sticking with dobutamine for pharmacological stress testing.
A study of adenosine safety conducted by researchers at St. Marien Hospital in Bonn, Germany, may put those concerns to rest. Dr. Karol Miszlaski-Jamka did record minor side effects, such as facial flushing and mild shortness of breath, in 81% of the 645 patients who underwent adenosine-stress contrast MR. But major side effects were limited, including 23 cases of transient high-degree atrioventricular block that resolved spontaneously, one case of severely increased blood pressure, and two instances of claustrophobia.
Study affirms safety . . .
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
